Cargando…
Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist’s Perspective
Biomarker testing has become standard of care for patients diagnosed with non-small cell lung carcinoma (NSCLC). Although, it can be successfully performed in circulating tumor cells, at present, the vast majority of investigations are carried out using direct tumor sampling, either through aspirati...
Autores principales: | Brega, Elisa, Brandao, Guilherme |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099940/ https://www.ncbi.nlm.nih.gov/pubmed/25077070 http://dx.doi.org/10.3389/fonc.2014.00182 |
Ejemplares similares
-
Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists
por: Brcic, Luka, et al.
Publicado: (2020) -
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation
por: Gosney, J.R., et al.
Publicado: (2023) -
Thymic carcinomas vs. lung carcinomas—pathologist’s perspective: extended abstract
por: Szolkowska, Malgorzata
Publicado: (2022) -
Diminutive and Small Colorectal Polyps: The Pathologist's Perspective
por: Kang, Yun Kyung
Publicado: (2014) -
Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)